Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
174 hedge funds and large institutions have $561M invested in Day One Biopharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 71 increasing their positions, 55 reducing their positions, and 34 closing their positions.
55% more call options, than puts
Call options by funds: $902K | Put options by funds: $581K
29% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 55
5% less funds holding
Funds holding: 184 → 174 (-10)
7.78% less ownership
Funds ownership: 92.94% → 85.16% (-7.8%)
24% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 34
25% less capital invested
Capital invested by funds: $747M → $561M (-$186M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$21.1M |
| 2 |
DM
Deerfield Management
New York
|
+$5.24M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$4.56M |
| 4 |
Renaissance Technologies
New York
|
+$4.49M |
| 5 |
Morgan Stanley
New York
|
+$4.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$45.6M |
| 2 |
ECM
Estuary Capital Management
Wayzata,
Minnesota
|
-$26.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.2M |
| 4 |
BCM
Boxer Capital Management
San Diego,
California
|
-$9.44M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
-$9.32M |
DAWN Hedge Fund Activity: Q2 2025 in Review
174 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q2 2025, worth a combined $561M — down 25% from $747M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of DAWN and 26 opened new positions — a net loss of 8 holders — while 55 trimmed existing stakes and 71 added.
The largest buyer was BlackRock, adding an estimated $21.1M. The largest seller was RA Capital Management, exiting entirely with an estimated $45.6M sold.
- 174 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q2 2025, down from 184 in Q1 2025.
- Funds reported $561M of Day One Biopharmaceuticals stock for Q2 2025, down 25% quarter-over-quarter.
- 26 funds opened new Day One Biopharmaceuticals positions in Q2 2025 and 34 closed out, a net change of -8 holders.
- The largest Day One Biopharmaceuticals buyer in Q2 2025 was BlackRock, an estimated $21.1M added.
- The largest Day One Biopharmaceuticals seller in Q2 2025 was RA Capital Management, an estimated $45.6M sold.
Based on aggregated 13F filings for Q2 2025.